Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, It's time to move on! diabetes care 2015;38:170-175

Diabetes Care

Volumn 38, Issue 6, 2015, Pages e95-

  Genuth, Saul ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADD ON THERAPY; COHORT ANALYSIS; HUMAN; HYPOGLYCEMIA; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; DIABETES MELLITUS, TYPE 2; FEEDING BEHAVIOR;

DIABETES MELLITUS, TYPE 2; FOOD HABITS; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; SULFONYLUREA COMPOUNDS;

EID: 84937512359     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-0519     Document Type: Note

References (5)

1. Schrijnders D, Houweling ST, Landman GWD. Comment on Genuth. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's time tomove on! Diabetes Care 2015;38: 170-175 (Letter). Diabetes Care 2015;38:e94. DOI:10.2337/dc15-0293.
2. Genuth S. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's time to move on! Diabetes Care 2015;38: 170-175.
3. Abrahamson MJ. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? Yes, they continue to serve us well! Diabetes Care 2015;38:166-169.
4. Landman GW, de Bock GH, van Hateren KJ, et al. Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials. PLoS One 2014;9:e82880.
5. Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011;32:1900-1908.